Marina Colella

Dr. Marina Colella

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJosé Thiago de Souza de Castro
José Thiago de Souza de Castro
SASimone Appenzeller
Simone Appenzeller
MCMarina Colella
Marina Colella
GYGabriela Yamaguti-Hayakawa
Gabriela Yamaguti-Hayakawa
EPErich Vinícius De Paula
Erich Vinícius De Paula
FOFernanda A. Orsi
Fernanda A. Orsi
Background and purpose: Thrombotic microangiopathy (TMA) is a group of microvascular occlusive disorders that presents with neurological involvement in up to 87% of the cases. Although the central nervous system (CNS) is an important target organ in TMA, the role of neurological manifestations in the disease clinical course is not well established. In this study, we described the neurological manifestations and CNS radiological aspects in patients with a first, acute TMA event. We also examined the association between severe neurological involvement and adverse clinical outcomes in TMA. Methods: A cohort of patients diagnosed with a first TMA event between 1995 and 2016 was included, their medical charts and imaging tests were retrospectively evaluated. Results: A total of 49 patients were included, 85.7% were women and the mean age was 36.5 years-old (SD 13.0). Neurological manifestations were described in 85.7% of the patients, most of them (88%) were considered severe and consisted of confusion, compromised sensorimotor function, stupor, seizures, and personality change. Imaging tests were performed in 62% of the patients with neurological manifestations and detected acute CNS lesions, such as posterior reversible encephalopathy syndrome, hemorrhagic and ischemic stroke were observed, in 7 (27%) of them. While the need for intensive care unit admission was greater and longer among patients with severe neurological manifestations, the number of plasma exchange sessions, the total duration of hospitalization and in-hospital death were similar between groups. Conclusions: Severe neurological manifestations are common in first TMA events and are responsible for a worse disease presentation at admission. While the effect of neurological manifestations on acute TMA clinical course seems to be modest, these manifestations may have an important impact on the development of chronic cognitive impairment, which highlights the need for proper diagnosis and treatment.

21 May 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MCMarina Colella
Marina Colella
FOFernanda A. Orsi
Fernanda A. Orsi
EAElizio C. F. Alves
Elizio C. F. Alves
GDGabriela de F. Delmoro
Gabriela de F. Delmoro
GYGabriela G. Yamaguti‐Hayakawa
Gabriela G. Yamaguti‐Hayakawa
JAJoyce M. Annichino‐Bizzacchi
Joyce M. Annichino‐Bizzacchi
Background The optimum second-line treatment or best sequence of treatments for immune thrombocytopenia are yet to be determined. Our institution has accumulated extensive experience regarding efficacy and safety of dapsone as second-line therapy for immune thrombocytopenia patients. Patients/methods Here we report our experience in a retrospective study, including 122 patients, with a median treatment duration with dapsone of six months and a median follow-up period of 3.4 years. Results and conclusions The overall response rate in this cohort was 66%, including 24% of complete responses. Among responders, in 24% a relapse occurred while on treatment. Therefore, a sustained response was observed in 51% of patients. Interestingly, 81% of the responders maintained the response after the interruption of treatment, for a median time of 26 months. Side effects were reported in 16% of the patients in this cohort and treatment was interrupted due to side effects in 11% of patients. The main cause in these cases was hemolytic anemia and methemoglobinemia. Reductions in hemoglobin levels during the use of dapsone were seen in 94% of the patients. Responders presented significantly greater reductions in their hemoglobin levels than non-responders did: median hemoglobin drop of 1.9g/dL vs 1.2g/dL (P=0.004). Our findings suggest that dapsone has adequate efficacy and is well tolerated. Although the mechanism of action is still unclear, our observation that the degree in the drop of hemoglobin is greater in responders suggest a possible role of the blockage of the reticuloendothelial system in the therapeutic effect of the drug.

17 August 2017 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
SSSabrina da Silva Saraiva
Sabrina da Silva Saraiva
BMBruna de Moraes Mazetto
Bruna de Moraes Mazetto
LTLais Quinteiro Tobaldine
Lais Quinteiro Tobaldine
MCMarina Colella
Marina Colella
EPErich Vinícius De Paula
Erich Vinícius De Paula
FOFernanda A. Orsi
Fernanda A. Orsi

22 June 2017 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
SMSamuel Souza Medina
Samuel Souza Medina
LSLúcia Helena Siqueira
Lúcia Helena Siqueira
MCMarina Colella
Marina Colella
GYGabriela Goes Yamaguti-Hayakawa
Gabriela Goes Yamaguti-Hayakawa
BDBruno Kosa Lino Duarte
Bruno Kosa Lino Duarte
MOMargareth Ozelo
Margareth Ozelo
Thrombocytopenia can occur in different circumstances during childhood and although immune thrombocytopenia is its most frequent cause, it is important to consider other conditions, especially when there is a persistent or recurrent low platelet count. We report two cases of intermittent thrombocytopenia, previously misdiagnosed as immune thrombocytopenia. Both cases described were boys who presented with an intermittent pattern of thrombocytopenia, with a persistently low mean platelet volume. In both patients, peripheral blood smear revealed small platelets and flow cytometry showed low expression of Wiskott-Aldrich syndrome protein (WASP) in leucocytes. Molecular analysis of the first case identified a mutation in exon 2 of the gene coding for WASP, leading to a p.Thr45Met amino acid change and confirming the diagnosis of X-linked thrombocytopenia. In the second case, a novel missense mutation in exon 2 of the gene coding for WASP was detected, which resulted in a p.Pro58Leu amino acid change. These two rare presentations of thrombocytopenia highlight the importance of evaluating the peripheral blood smear in the presence of recurrent or persistent thrombocytopenia and show that failing to do so can lead to misdiagnoses. Since thrombocytopenia may be found in pediatric outpatient clinic, increased awareness among general pediatricians will help to improve the differential diagnosis of this condition.

1 March 2012 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
MCMarina Colella
Marina Colella
MFMaiara M.L. Fiusa
Maiara M.L. Fiusa
FOFernanda A. Orsi
Fernanda A. Orsi
EPErich V. de Paula
Erich V. de Paula
JAJoyce M. Annichino-Bizzacchi
Joyce M. Annichino-Bizzacchi
New portable devices for the measurement of the prothrombin time and the international normalized ratio (INR) from capillary blood samples have demonstrated to have good correlation with classic laboratory methods in multiple clinical settings. In this study, we evaluated the performance of the point-of-care device CoaguChek XS (CoaguChek XS; Roche Diagnostics, Basel, Switzerland), comparing the INR results with the standard laboratory method (automatic coagulometer) in an outpatient anticoagulation clinic. Results were compared by linear regression and Bland–Altman plot. Two hundred paired results were collected from 170 patients in a period of 90 days. The main indications for anticoagulation were prophylaxis of venous thromboembolic events, atrial fibrillation and prosthetic heart valves. Mean INR results obtained with the portable device and with the standard laboratory method were 2.22 ± 0.70 and 2.30 ± 0.77, respectively. The proportion of patients with supratherapeutic INRs was 13.5%. The CoaguChek XS monitor tended to underestimate the INR on average by 0.08 U. The correlation coefficient (R) between the two methods was 0.91 (P < 0.0001). The CoaguChek XS device is suitable for INR monitoring in patients in outpatient oral anticoagulation clinics.

1 November 2019 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
ACAna Clara Ladeira Cruz
Ana Clara Ladeira Cruz
MCMarina Colella
Marina Colella
EPErich Vinícius De Paula
Erich Vinícius De Paula
JAJoyce Maria Annichino-Bizzacchi
Joyce Maria Annichino-Bizzacchi
FOFernanda A. Orsi
Fernanda A. Orsi